CN102641335A - Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof Download PDFInfo
- Publication number
- CN102641335A CN102641335A CN2012101579309A CN201210157930A CN102641335A CN 102641335 A CN102641335 A CN 102641335A CN 2012101579309 A CN2012101579309 A CN 2012101579309A CN 201210157930 A CN201210157930 A CN 201210157930A CN 102641335 A CN102641335 A CN 102641335A
- Authority
- CN
- China
- Prior art keywords
- respiratory tract
- upper respiratory
- radix
- tract infection
- thick paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating upper respiratory tract viral infection and a preparation method thereof. The composition comprises the following active pharmaceutical ingredients in parts by weight: 5-25g of perilla leaf, 5-25g of platycodon root, 5-25g of great burdock achene, 5-25g of willowleaf swallowwort rhizome, 5-25g of Chinese thorowax root, 5-25g of perilla fruit, 5-25g of schizonepeta spike, 5-25g of baical skullcap root, 5-25g of white mulberry root-bark and 1-15g of liquoric root. The active pharmaceutical ingredients can be matched with excipients and a flavoring agent to be directly or indirectly prepared into pharmaceutically acceptable capsules, oral liquid, granules, syrup, tablets, effervescent particles, dropping pills, aerosol, spraying agent, gargle, mouthwash and a variety of formulations via conventional process steps. The traditional Chinese medicine composition can be clinically used for treating or preventing the upper respiratory tract viral infection caused by influenza virus, rhino virus, coronavirus, parainfluenza virus, respiratory syncytial virus, adenovirus and the like and further has the advantages of good curative effect and high cure rate.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly about the Chinese medicine composition and preparation method thereof of treatment upper respiratory tract infection.Wherein, described upper respiratory tract infection is the upper respiratory tract infection that influenza virus, rhinovirus, coronavirus, parainfluenza virus, respiratory syncytial virus, adenovirus etc. are caused.
Background technology
Upper respiratory tract infection is meant the acutely inflamed general name between nasal cavity to throat, is the modal a kind of infectious disease of respiratory tract.Cause by virus about 70-80% that minority is (Zhu Guiqing, respiratory medicine, People's Health Publisher, in March, 1984) due to the antibacterial.Bacterial infection often is secondary to after the viral infection.Be characteristic with symptoms such as heating, aversion to cold, headache, nasal obstruction, sneeze, watery nasal discharge, pharyngalgia, cough, hoarsenesss clinically.These disease four seasons, any age all can fall ill, and through containing the spittle, the droplet of virus, or propagate through the apparatus that pollutes.Often when Abwehrkraft des Koepers reduces, as catch cold, tired, situation such as drench with rain, the former virus that has existed or invaded by the external world is or/and antibacterial, the ramp breeding causes infecting.Thereby how can cure the heat generation upper respiratory tract infection efficiently and effectively and seem particularly important.
The common virus that causes upper respiratory tract infection has influenza virus, rhinovirus, coronavirus, parainfluenza virus, respiratory syncytial virus, adenovirus etc., and is wherein common with rhinovirus.Going up of general type felt: the lighter Chang Yu nasal obstruction, sneeze, watery nasal discharge, dry cough and pharyngalgia occurred after suffering from cold 1-3 days, can be with heating, and some morbidity can have paroxysmal umbilicus week pain in early days; Relevant with enterospasm and adenomesenteritis due to the heating; Especially the infant local symptom is not obvious for weight person, but General Symptoms is heavy, can play hyperpyrexia, cough, poor appetite, companion's vomiting, diarrhoea suddenly; Hyperpyrexia convulsion appears in severe patient, is commonly called as " hyperpyrexia convulsion ".The visible pharyngeal congestion of health check-up, antiadoncus, pulmonary's respiratory murmur is normal.
Influenza: be called for short influenza; Be to be that first, second, the third three type influenza viruss are through droplet transmission by the acute respiratory infectious disease pathogens that influenza virus causes; Anxious hyperpyrexia, weak, muscular soreness of whole body and the slight respiratory symptom of rising arranged clinically; The course of disease is short, middle age and be prone to concurrent pneumonia with chronic respiratory tract disease or cardiac.Influenza virus very easily makes a variation with the first type especially, often cause break out, popular or be very popular.Existing five worldwide pandemic discipline are carried since this century, and wherein serious with the big influenza of Spain in 1918, death toll reaches 2,000 ten thousand more than.China is from existing 12 medium or medium above influenza pandemic of nineteen fifty-three to 1976 year, each popularly causes that by influenza A virus the epidemic situation of influenza is main to distribute and to break out for a short time after entering eighties, do not have tangible popular generation.
At present, doctor trained in Western medicine is treated the ribavirins that adopt such as rhinovirus, coronavirus more both at home and abroad.Because the hypotype of rhinovirus, coronavirus is more, be difficult to use vaccine to prevent the generation of virus.The method of preventing and treating to influenza virus is exactly to prevent the generation of virus according to antigen-antibody theory utilization vaccine, but because the antigen of virus is constantly taking place to make a variation, vaccine often also just loses effectiveness.And be used for antiviral drug, based on the variability of virus and the problems such as drug resistance of medicine, make the problem of preventing and treating of virus still very severe.
For respiratory system disease, theory of Chinese medical science is thought " lung governing qi, department breathe ".Here said " gas ", one side is meant the gas of breathing, is meant that on the one hand lung and other internal organs show the function of breathing aspect." lung opening at nose and throat close fur outward "." element is asked. cough opinion " say: " fur receives pathogen earlier for fur person, the closing also of lung, and pathogen is to close also from it ", what say is that lung communicates with the external world through nasopharynx part and skin hair key, just as one barrier, is responsible for the defensive enginery of human body.External wind, cold, summer-heat, wet, dry, fiery paathogenic factors such as (being referred to as the heresy of six climate exopathogens) are often passed through nasopharynx part and fur; At first invade in lung; Causing that lung qi loses in a surname sends out or during respectful falling, all can make abnormal rising of lung-QI and cause cough, pant, symptom such as expectoration, this belongs to the exogenous cough.The heresy of six climate exopathogens is caused a disease, and is main with ailment said due to cold or exposure how, and the winter is windy cold, windy heat of spring, and many heat-damp in summers of summer, the autumn is windy dry, and plum rain season is held damp under the arm more.But not the time gas when holding under the arm row virus hurt sb.'s feelings, then often be not limited to season, and the state of an illness is multiple, be prone to cause infect popular.And influenza, the pathogenic wind-warm category of genus epidemic febrile disease, the genus influenza, its characteristics have also just been included the characteristics of diseases caused by exogenous pathogenic factor respiratory disease: seasonable, it is high to generate heat, and the state of an illness weighs, and infection is popular by force, scope is wide.
Advantages such as Chinese medicine has not only that drug resistance is low, side effect and untoward reaction are few; And suppress virus replication in addition, regulate immunologic function, improve blood circulation, comprehensive effects such as antipyretic-antalgic and anti-inflammation, it has special advantages and vast potential for future development aspect control viral infection.
Summary of the invention
Therefore, still there is greatly demand in people's Chinese medicine preparation that curative effect is better treated upper respiratory tract infection.Up to now, also do not find the report of any relevant pharmaceutical composition of the present invention.The inventor is through research repeatedly, and through external and repeated validation clinical trial, found the Chinese medicine composition that the treatment of better curative effect upper respiratory tract infection is arranged finally, thereby accomplished the present invention.This research is adopted targetedly and has unique prepared from traditional Chinese medicines of treating the upper respiratory tract infection effect to form to above-mentioned etiology and pathogenesis.Said composition mainly is made up of Folium Perillae, Radix Platycodonis, Fructus Arctii, Rhizoma Cynanchi Stauntonii, Radix Bupleuri, Fructus Perillae, Herba Schizonepetae, Radix Scutellariae, Cortex Mori, Radix Glycyrrhizae; Effect with lung qi dispersing heat clearing away, relieving cough and resolving phlegm can be used for the upper respiratory tract infection of treating or preventing to be caused by influenza virus, rhinovirus, coronavirus, parainfluenza virus, respiratory syncytial virus, adenovirus etc. clinically.
The objective of the invention is: overcome the deficiency of prior art, provide a kind of and can effectively treat or prevent upper respiratory tract infection that is caused by influenza virus, rhinovirus, coronavirus, parainfluenza virus, respiratory syncytial virus, adenovirus etc. and the Chinese medicine composition that has no side effect.
Another object of the present invention is: the method for preparing of this Chinese medicine composition is provided, has satisfied the demand in market.
For reaching better therapeutic, medicine of the present invention can combine with crude drug Folium Mori or Radix Asteris.
For reaching better therapeutic, medicine of the present invention also can combine with the crude drug Folium Eriobotryae or the Radix Stemonae.
For reaching better therapeutic, medicine of the present invention also can combine with crude drug Herba Ephedrae or Pericarpium Citri Reticulatae.
For reaching better therapeutic, medicine of the present invention also can combine with crude drug Pumex or Concretio Silicea Bambusae.
The technical solution adopted for the present invention to solve the technical problems is: treat the Chinese medicine composition of upper respiratory tract infection, comprise the crude drug of following parts by weight: Folium Perillae 5-25 restrains, Radix Platycodonis 5-25 restrains, Fructus Arctii 5-25 restrains, Rhizoma Cynanchi Stauntonii 5-25 restrains, Radix Bupleuri 5-25 restrains, Fructus Perillae 5-25 restrains, Herba Schizonepetae 5-25 restrains, Radix Scutellariae 5-25 restrains, Cortex Mori 5-25 restrains, Radix Glycyrrhizae 1-15 restrains.
Preferable amount is: Folium Perillae 5-20 gram, Radix Platycodonis 5-20 gram, Fructus Arctii 5-20 gram, Rhizoma Cynanchi Stauntonii 5-20 gram, Radix Bupleuri 5-20 gram, Fructus Perillae 5-20 gram, Herba Schizonepetae 5-20 gram, Radix Scutellariae 5-20 gram, Cortex Mori 5-20 gram, Radix Glycyrrhizae 3-10 gram.
The method for preparing of medicine of the present invention is following:
Get crude drug Folium Perillae, Radix Platycodonis, Fructus Arctii, Rhizoma Cynanchi Stauntonii, Radix Bupleuri, Fructus Perillae, Herba Schizonepetae, Radix Scutellariae, Cortex Mori, Radix Glycyrrhizae decocte with water merging filtrate, concentrate, cool off; Adding ethanol makes and contains alcohol amount 20-80% (V/V); Reclaim ethanol, make supernatant concentration become thick paste, subsequent use.The thick paste of preparation is added capsule adjuvant commonly used, and dry, pulverizing incapsulates, and can be prepared into the capsule of treatment upper respiratory tract infection; Or thick paste and granule adjuvant commonly used mixed, granulate, dry be distributed into bag, can be prepared into the granule of treating upper respiratory tract infection; Or thick paste and oral liquid adjuvant commonly used mixed, boiling, thin up leaves standstill, and filters, and mixing is distributed into bottle, can be prepared into the oral liquid of treating upper respiratory tract infection; Or thick paste added sucrose, correctives, antiseptic, and boiling, thin up is to 1000ml; Leave standstill, filter mixing; Packing promptly gets the syrup of treating upper respiratory tract infection, wherein said sucrose weight＞450g; Said correctives is stevioside, saccharin sodium, acesulfame-K, glycyrrhizin, thiacyclohexane sulfamic acid, agedoite, alcohol sugar, radix asparagi sweet extract, Mentholum, various essence and various fruity material; Consumption is 0.1 ~ 10%, and said antiseptic is sorbic acid and k-na salt consumption thereof for＜0.3%, methyl hydroxybenzoate class consumption is＜0.05%, and the packaging material that said packing is used is vial, plastic bottle; Maybe thick paste and the tablet adjuvant commonly used with preparation mix, tabletting, can be prepared into the tablet of treating upper respiratory tract infection.
If also combine with crude drug Folium Mori or Radix Asteris, its preparation method is:
Get crude drug Folium Perillae, Radix Platycodonis, Fructus Arctii, Rhizoma Cynanchi Stauntonii, Radix Bupleuri, Fructus Perillae, Herba Schizonepetae, Radix Scutellariae, Cortex Mori, Radix Glycyrrhizae, Folium Mori or Radix Asteris decocte with water merging filtrate, concentrate, cool off; Adding ethanol makes and contains alcohol amount 20-80% (V/V); Reclaim ethanol, make supernatant concentration become thick paste, subsequent use.The thick paste of preparation is added capsule adjuvant commonly used, and dry, pulverizing incapsulates, and can be prepared into the capsule of treatment upper respiratory tract infection; Or thick paste and granule adjuvant commonly used mixed, granulate, dry be distributed into bag, can be prepared into the granule of treating upper respiratory tract infection; Or thick paste and oral liquid adjuvant commonly used mixed, boiling, thin up leaves standstill, and filters, and mixing is distributed into bottle, can be prepared into the oral liquid of treating upper respiratory tract infection; Or thick paste added sucrose, correctives, antiseptic, and boiling, thin up is to 1000ml; Leave standstill, filter mixing; Packing promptly gets the syrup of treating upper respiratory tract infection, wherein said sucrose weight＞450g; Said correctives is stevioside, saccharin sodium, acesulfame-K, glycyrrhizin, thiacyclohexane sulfamic acid, agedoite, alcohol sugar, radix asparagi sweet extract, Mentholum, various essence and various fruity material; Consumption is 0.1 ~ 10%, and said antiseptic is sorbic acid and k-na salt consumption thereof for＜0.3%, methyl hydroxybenzoate class consumption is＜0.05%, and the packaging material that said packing is used is vial, plastic bottle; Maybe thick paste and the tablet adjuvant commonly used with preparation mix, tabletting, can be prepared into the tablet of treating upper respiratory tract infection.
If also combine with the crude drug Folium Eriobotryae or the Radix Stemonae, its preparation method is:
Get crude drug Folium Perillae, Radix Platycodonis, Fructus Arctii, Rhizoma Cynanchi Stauntonii, Radix Bupleuri, Fructus Perillae, Herba Schizonepetae, Radix Scutellariae, Cortex Mori, Radix Glycyrrhizae, Folium Mori or Radix Asteris, Folium Eriobotryae or Radix Stemonae decocte with water merging filtrate, concentrate, cool off; Adding ethanol makes and contains alcohol amount 20-80% (V/V); Reclaim ethanol; Make supernatant concentration become thick paste, subsequent use.The thick paste of preparation is added capsule adjuvant commonly used, and dry, pulverizing incapsulates, and can be prepared into the capsule of treatment upper respiratory tract infection; Or thick paste and granule adjuvant commonly used mixed, granulate, dry be distributed into bag, can be prepared into the granule of treating upper respiratory tract infection; Or thick paste and oral liquid adjuvant commonly used mixed, boiling, thin up leaves standstill, and filters, and mixing is distributed into bottle, can be prepared into the oral liquid of treating upper respiratory tract infection; Or thick paste added sucrose, correctives, antiseptic, and boiling, thin up is to 1000ml; Leave standstill, filter mixing; Packing promptly gets the syrup of treating upper respiratory tract infection, wherein said sucrose weight＞450g; Said correctives is stevioside, saccharin sodium, acesulfame-K, glycyrrhizin, thiacyclohexane sulfamic acid, agedoite, alcohol sugar, radix asparagi sweet extract, Mentholum, various essence and various fruity material; Consumption is 0.1 ~ 10%, and said antiseptic is sorbic acid and k-na salt consumption thereof for＜0.3%, methyl hydroxybenzoate class consumption is＜0.05%, and the packaging material that said packing is used is vial, plastic bottle; Maybe thick paste and the tablet adjuvant commonly used with preparation mix, tabletting, can be prepared into the tablet of treating upper respiratory tract infection.
If also combine with crude drug Herba Ephedrae or Pericarpium Citri Reticulatae, its preparation method is:
Get crude drug Folium Perillae, Radix Platycodonis, Fructus Arctii, Rhizoma Cynanchi Stauntonii, Radix Bupleuri, Fructus Perillae, Herba Schizonepetae, Radix Scutellariae, Cortex Mori, Radix Glycyrrhizae, Folium Mori or Radix Asteris, Folium Eriobotryae or the Radix Stemonae, Herba Ephedrae or Pericarpium Citri Reticulatae decocte with water merging filtrate, concentrate, cool off; Adding ethanol makes and contains alcohol amount 20-80% (V/V); Reclaim ethanol; Make supernatant concentration become thick paste, subsequent use.The thick paste of preparation is added capsule adjuvant commonly used, and dry, pulverizing incapsulates, and can be prepared into the capsule of treatment upper respiratory tract infection; Or thick paste and granule adjuvant commonly used mixed, granulate, dry be distributed into bag, can be prepared into the granule of treating upper respiratory tract infection; Or thick paste and oral liquid adjuvant commonly used mixed, boiling, thin up leaves standstill, and filters, and mixing is distributed into bottle, can be prepared into the oral liquid of treating upper respiratory tract infection; Or thick paste added sucrose, correctives, antiseptic, and boiling, thin up is to 1000ml; Leave standstill, filter mixing; Packing promptly gets the syrup of treating upper respiratory tract infection, wherein said sucrose weight＞450g; Said correctives is stevioside, saccharin sodium, acesulfame-K, glycyrrhizin, thiacyclohexane sulfamic acid, agedoite, alcohol sugar, radix asparagi sweet extract, Mentholum, various essence and various fruity material; Consumption is 0.1 ~ 10%, and said antiseptic is sorbic acid and k-na salt consumption thereof for＜0.3%, methyl hydroxybenzoate class consumption is＜0.05%, and the packaging material that said packing is used is vial, plastic bottle; Maybe thick paste and the tablet adjuvant commonly used with preparation mix, tabletting, can be prepared into the tablet of treating upper respiratory tract infection.
If also combine with crude drug Pumex or Concretio Silicea Bambusae, its preparation method is:
Get crude drug Folium Perillae, Radix Platycodonis, Fructus Arctii, Rhizoma Cynanchi Stauntonii, Radix Bupleuri, Fructus Perillae, Herba Schizonepetae, Radix Scutellariae, Cortex Mori, Radix Glycyrrhizae, Folium Mori or Radix Asteris, Folium Eriobotryae or the Radix Stemonae, Herba Ephedrae or Pericarpium Citri Reticulatae, Pumex or Concretio Silicea Bambusae decocte with water merging filtrate, concentrate, cool off; Adding ethanol makes and contains alcohol amount 20-80% (V/V); Reclaim ethanol; Make supernatant concentration become thick paste, subsequent use.The thick paste of preparation is added capsule adjuvant commonly used, and dry, pulverizing incapsulates, and can be prepared into the capsule of treatment upper respiratory tract infection; Or thick paste and granule adjuvant commonly used mixed, granulate, dry be distributed into bag, can be prepared into the granule of treating upper respiratory tract infection; Or thick paste and oral liquid adjuvant commonly used mixed, boiling, thin up leaves standstill, and filters, and mixing is distributed into bottle, can be prepared into the oral liquid of treating upper respiratory tract infection; Or thick paste added sucrose, correctives, antiseptic, and boiling, thin up is to 1000ml; Leave standstill, filter mixing; Packing promptly gets the syrup of treating upper respiratory tract infection, wherein said sucrose weight＞450g; Said correctives is stevioside, saccharin sodium, acesulfame-K, glycyrrhizin, thiacyclohexane sulfamic acid, agedoite, alcohol sugar, radix asparagi sweet extract, Mentholum, various essence and various fruity material; Consumption is 0.1 ~ 10%, and said antiseptic is sorbic acid and k-na salt consumption thereof for＜0.3%, methyl hydroxybenzoate class consumption is＜0.05%, and the packaging material that said packing is used is vial, plastic bottle; Maybe thick paste and the tablet adjuvant commonly used with preparation mix, tabletting, can be prepared into the tablet of treating upper respiratory tract infection.
Chinese medicine composition of the present invention can be prepared into the above dosage form of any pharmaceutics: capsule, oral liquid, granule, syrup, tablet, effervescent granule, drop pill, aerosol, spray, gargarisma, collutory; Said tablet is oral cavity disintegration tablet, effervescent tablet.
Medicament selection Folium Perillae of the present invention, Radix Platycodonis, Fructus Arctii, Rhizoma Cynanchi Stauntonii, Radix Bupleuri, Fructus Perillae, Herba Schizonepetae, Radix Scutellariae, Cortex Mori, Radix Glycyrrhizae make up.Make each efficacy of drugs produce synergism these drug regimens, thereby can effectively treat upper respiratory tract infection property disease.Wherein hot, the tepor of Folium Perillae is nontoxic, returns spleen, lung two warps, cures mainly affection of exogenous wind-cold, fever with aversion to cold, and it is lossless to have a headache, monarch drug in the cough and asthma side of being; Select Radix Platycodonis, Fructus Arctii, Rhizoma Cynanchi Stauntonii, Radix Bupleuri, Fructus Perillae, Herba Schizonepetae, Radix Scutellariae, Cortex Mori for use; Be because of Radix Platycodonis bitter in the mouth, suffering, slightly warm in nature, go into lung meridian, the ability expelling phlegm for arresting cough; And lung qi dispersing, evacuation of pus effect are arranged, be used for cough with copious phlegm, laryngopharynx swelling and pain, lung abscess vomiting pus, fullness in the chest and hypochondriac pain; Fructus Arctii is hot, bitter, cold in nature, attaches to the lung and stomach meridians, and dispelling wind and heat pathogens, heat-clearing and toxic substances removing rash, lung qi dispersing sore-throat relieving loose swollen; Rhizoma Cynanchi Stauntonii is hot, bitter, tepor, returns lung meridian, and merit is apt to lowering the adverse-rising QI to resolve phlegm, is used for cough with copious phlegm, asthma; Radix Bupleuri is bitter, be slightly cold, and return Liver Channel, gallbladder meridian, function: evacuate and bring down a fever, the yang invigorating soothing liver-QI cures mainly cold, fever, alternate attack of chill and fever; Fructus Perillae is hot, warm, returns lung, spleen channel, the sending down the abnormal ascending QI expectorant is arranged, relievings asthma, the effect of intestine moistening; Herba Schizonepetae is hot, tepor is returned lung, Liver Channel, and the effect of induce sweat diffusing wind, rash is arranged; Radix Scutellariae is famous clearing away heat-fire Chinese medicine, and Radix Scutellariae is bitter, cold, heat clearing and damp drying, eliminating fire and detoxication, the excess-heat of the kind lung heat clearing fire and the part of the body cavity above the diaphragm housing the heart and lungs; Cortex Mori is sweet, cold, goes into lung meridian, but eliminating pathogen from the lung for relieving asthma, inducing diuresis to remove edema; More than eight medicines be that ministerial drug and adjuvant drug are assisted a ruler in governing a country monarch drug jointly; Radix Glycyrrhizae is as the existing heat-clearing and toxic substances removing of messenger drug, the merit of expelling phlegm for arresting cough, but coordinating the actions of various ingredients in a prescription again; All medicine compatibilities are dredged clearly and usefulness, go up and down and throw altogether, the merit of playing lung qi dispersing heat clearing away, relieving cough and resolving phlegm altogether.
In order to reach good curative effect, medicine of the present invention also makes up with Folium Mori or Radix Asteris.This is because of Folium Mori sweet in the mouth, hardship, cold in nature, returns lung, Liver Channel, effect: dispelling wind and heat pathogens, and clearing away lung-heat and moistening for dryness, suppressing liver-YANG, liver heat removing and eyesight improving, cooling blood for hemostasis is used for dispelling wind and heat pathogens, clearing away lung-heat and moistening for dryness, liver heat removing and eyesight improving; Radix Asteris is bitter, hot, sweet, tepor, returns lung meridian, and merit is apt to the moistening the lung and resolving phlegm cough-relieving, is used for bringing up phlegm when one coughs more.
In order to reach better therapeutic, medicine of the present invention also makes up with the Folium Eriobotryae or the Radix Stemonae.This is because of the Folium Eriobotryae hardship, is slightly cold, and attaches to the lung and stomach meridians, and merit is apt to clearing away lung-heat to relieve cough, stopping nausea and vomiting by lowering the adverse flow of QI, is used for the cough due to lung-heat, QI rising in reverse order dyspnea with rapid respiration, gastropyretic vomiting, hiccup; The Radix Stemonae is sweet, bitter, tepor, returns lung meridian, has the effect of nourishing the lung to keep the adverse QI downward cough-relieving, parasite killing.
In order to obtain optimum curative effect, medicine of the present invention also makes up with Herba Ephedrae or Pericarpium Citri Reticulatae.This is because of Herba Ephedrae suffering, little hardship, temperature, returns lung, urinary bladder channel, diaphoresis cold expelling, depressed lung-energy dispersing, inducing diuresis to remove edema; Pericarpium Citri Reticulatae temperature, suffering, bitter are returned lung, spleen channel, have cold expelling, dampness, and promoting the circulation of QI, the merit of expectorant is used for the cough due to wind and cold, the itching of the throat abundant expectoration.
In order to obtain optimum curative effect, medicine of the present invention also makes up with Pumex or Concretio Silicea Bambusae.This is salty because of Pumex, cold, returns lung, kidney channel, and merit is apt to removing heat from the lung and dissipating phlegm, hard masses softening and resolving, and inducing diuresis for treating stranguria syndrome is used for the expectorant heat syndrome cough and breathes heavily equivalent good; Concretio Silicea Bambusae is sweet, cold, GUIXIN, Liver Channel, and effect: removing heat-phlegm, the arresting convulsion that clears away heart-fire is used for the expectorant heat syndrome cough and breathes heavily infantile convulsion etc.
Chinese medicine composition of the present invention be in the anti-respirovirus clinical practice of the traditional Chinese medical science for many years, sum up use out through proved recipe, the experimental basis of science in addition, each component can be brought into play pharmacological action separately; Can play mutual synergism again, pharmacological action is strengthened, prescription rationally; The flavour of a drug refine, this side is used for treatment or prevention upper respiratory tract infection, determined curative effect; And have no side effect; At epidemic period, it is all effective with prevention to be used for treatment as general side, and dosage form and preparation technology are fit to industrialized mass.
The specific embodiment
The present invention treats or prevent the Chinese medicine composition of upper respiratory tract infection, comprises the crude drug of following parts by weight: Folium Perillae 5-25 restrains, Radix Platycodonis 5-25 restrains, Fructus Arctii 5-25 restrains, Rhizoma Cynanchi Stauntonii 5-25 restrains, Radix Bupleuri 5-25 restrains, Fructus Perillae 5-25 restrains, Herba Schizonepetae 5-25 restrains, Radix Scutellariae 5-25 restrains, Cortex Mori 5-25 restrains, Radix Glycyrrhizae 1-15 restrains.For reaching good curative effect, medicine of the present invention combines with crude drug Folium Mori or Radix Asteris; For reaching better therapeutic, medicine of the present invention also combines with the crude drug Folium Eriobotryae or the Radix Stemonae; In order to obtain optimum curative effect, medicine of the present invention also combines with crude drug Herba Ephedrae or Pericarpium Citri Reticulatae; In order to obtain optimum curative effect, medicine of the present invention also combines with crude drug Pumex or Concretio Silicea Bambusae.
Embodiment 1:
Weighting raw materials Folium Perillae 15 grams, Radix Platycodonis 10 grams, Fructus Arctii 10 grams, Rhizoma Cynanchi Stauntonii 10 grams, Radix Bupleuri 10 grams, Fructus Perillae 10 grams, Herba Schizonepetae 10 grams, Radix Scutellariae 10 grams, Cortex Mori 10 grams, Radix Glycyrrhizae 10 grams; More than ten herbal medicines totally 105 the gram; The decocte with water merging filtrate, concentrate, cooling, add ethanol and make and contain the alcohol amount and be 20-80%, reclaim ethanol; Make supernatant concentration become thick paste, subsequent use.Add 2 times of 95% ethanol that cream is heavy in the thick paste, fully stir, leave standstill 24～48h under the room temperature; Get supernatant, precipitate is with 65% washing with alcohol 1～2 time, and cleaning mixture and supernatant merge; If any alcohol extract; Also merge with supernatant, filters clear and bright after, go into concentrating under reduced pressure jar or alcohol distillation column and reclaim ethanol and only do not have the alcohol flavor until medicinal liquid.The dilution of medicinal liquid adding distil water is heated to 100 ℃, makes coacervation of colloid, transfers pH4.5～5.0; 0～4 ℃ of cold preservation 24h of low temperature makes the colloidal precipitation of cohesion again, then, filters to clear and bright; Add an amount of correctives and antiseptic, after leaving standstill, filter clear and bright again; Low-temp storage is done last purification filtering before the fill, filtrating put the lamp inspection appearance under detection clear and bright after; Last mechanical irrigation is encapsulated in the straight tube easy-open lid nutrition bottle, and dress 10ml ± 4% promptly gets the oral liquid that the present invention treats upper respiratory tract infection in every oral liquid bottle.
Embodiment 2:
Weighting raw materials Folium Perillae 15 grams, Radix Platycodonis 10 grams, Fructus Arctii 10 grams, Rhizoma Cynanchi Stauntonii 10 grams, Radix Bupleuri 10 grams, Fructus Perillae 10 grams, Herba Schizonepetae 10 grams, Radix Scutellariae 10 grams, Cortex Mori 10 grams, Radix Glycyrrhizae 10 grams; More than ten herbal medicines totally 105 the gram; The decocte with water merging filtrate, concentrate, cooling, add ethanol and make and contain the alcohol amount and be 20-80%, reclaim ethanol; Make supernatant concentration become thick paste, subsequent use.Add beta-schardinger dextrin-; 180 ℃ of heating for dissolving, stirring, filtration, spray drying hot-air EAT; 80 ℃ of leaving air temps, spray powder adds flavoring agent, mixing; Material under 40 ℃ of temperature dry granulation, granulate, be distributed into bag, promptly get the granule that the present invention treats upper respiratory tract infection.
Embodiment 3:
Weighting raw materials Folium Perillae 15 grams, Radix Platycodonis 10 grams, Fructus Arctii 10 grams, Rhizoma Cynanchi Stauntonii 10 grams, Radix Bupleuri 10 grams, Fructus Perillae 10 grams, Herba Schizonepetae 10 grams, Radix Scutellariae 10 grams, Cortex Mori 10 grams, Radix Glycyrrhizae 10 grams, Folium Mori 10 grams; More than ten simply medicine totally 115 the gram, process oral liquid by embodiment 1 described method then.
Embodiment 4:
Weighting raw materials Folium Perillae 15 grams, Radix Platycodonis 10 grams, Fructus Arctii 10 grams, Rhizoma Cynanchi Stauntonii 10 grams, Radix Bupleuri 10 grams, Fructus Perillae 10 grams, Herba Schizonepetae 10 grams, Radix Scutellariae 10 grams, Cortex Mori 10 grams, Radix Glycyrrhizae 10 grams, Radix Asteris 10 grams; More than ten simply medicine totally 115 the gram, process granule by embodiment 2 described methods then.
Embodiment 5:
Weighting raw materials Folium Perillae 15 grams, Radix Platycodonis 10 grams, Fructus Arctii 10 grams, Rhizoma Cynanchi Stauntonii 10 grams, Radix Bupleuri 10 grams, Fructus Perillae 10 grams, Herba Schizonepetae 10 grams, Radix Scutellariae 10 grams, Cortex Mori 10 grams, Radix Glycyrrhizae 10 grams, Folium Mori 10 grams, Folium Eriobotryae 10 grams; More than 12 herbal medicines totally 125 the gram, process oral liquid by embodiment 1 described method then.
Embodiment 6:
Weighting raw materials Folium Perillae 15 grams, Radix Platycodonis 10 grams, Fructus Arctii 10 grams, Rhizoma Cynanchi Stauntonii 10 grams, Radix Bupleuri 10 grams, Fructus Perillae 10 grams, Herba Schizonepetae 10 grams, Radix Scutellariae 10 grams, Cortex Mori 10 grams, Radix Glycyrrhizae 10 grams, Radix Asteris 10 grams, the Radix Stemonae 10 grams; More than 12 herbal medicines totally 125 the gram, process granule by embodiment 2 described methods then.
Embodiment 7:
Weighting raw materials Folium Perillae 15 grams, Radix Platycodonis 10 grams, Fructus Arctii 10 grams, Rhizoma Cynanchi Stauntonii 10 grams, Radix Bupleuri 10 grams, Fructus Perillae 10 grams, Herba Schizonepetae 10 grams, Radix Scutellariae 10 grams, Cortex Mori 10 grams, Radix Glycyrrhizae 10 grams, Folium Mori 10 grams, Folium Eriobotryae 10 grams, Herba Ephedrae 10 grams; More than 13 herbal medicines 135g altogether, process oral liquid by embodiment 1 described method then.
Embodiment 8:
Weighting raw materials Folium Perillae 15 grams, Radix Platycodonis 10 grams, Fructus Arctii 10 grams, Rhizoma Cynanchi Stauntonii 10 grams, Radix Bupleuri 10 grams, Fructus Perillae 10 grams, Herba Schizonepetae 10 grams, Radix Scutellariae 10 grams, Cortex Mori 10 grams, Radix Glycyrrhizae 10 grams, Radix Asteris 10 grams, the Radix Stemonae 10 grams, Pericarpium Citri Reticulatae 10 grams; More than 13 herbal medicines 135g altogether, process granule liquid by embodiment 2 described methods then.
Embodiment 9:
Weighting raw materials Folium Perillae 15 grams, Radix Platycodonis 10 grams, Fructus Arctii 10 grams, Rhizoma Cynanchi Stauntonii 10 grams, Radix Bupleuri 10 grams, Fructus Perillae 10 grams, Herba Schizonepetae 10 grams, Radix Scutellariae 10 grams, Cortex Mori 10 grams, Radix Glycyrrhizae 10 grams, Folium Mori 10 grams, Folium Eriobotryae 10 grams, Herba Ephedrae 10 grams, Pumex 10 grams; More than ten four Chinese medicine things 145g altogether, process oral agents by embodiment 1 described method then.
Embodiment 10:
Weighting raw materials Folium Perillae 15 grams, Radix Platycodonis 10 grams, Fructus Arctii 10 grams, Rhizoma Cynanchi Stauntonii 10 grams, Radix Bupleuri 10 grams, Fructus Perillae 10 grams, Herba Schizonepetae 10 grams, Radix Scutellariae 10 grams, Cortex Mori 10 grams, Radix Glycyrrhizae 10 grams, Radix Asteris 10 grams, the Radix Stemonae 10 grams, Pericarpium Citri Reticulatae 10 grams, Concretio Silicea Bambusae 10 grams; More than ten four Chinese medicine things 145g altogether, process granule liquid by embodiment 2 described methods then.
Test Example 1: the external rhinovirus of Chinese medicine composition (HRV, laboratory observation N36)
Test philosophy: with people embryo epithelial cell is virus host, and working sample suppresses rhinovirus and causes people embryo epithelial cell lesion degree.
Test material and method:
1. Strain: rhinovirus (HRV, N36).
2. sample treatment: get that thick paste that embodiment 2,4,6,8,10 makes is dissolved in water and to process the solution bottling of 1000mg/ml respectively subsequent use; 3000rpm gets supernatant after centrifugal 20 minutes, and the sodium citrate with 50% is transferred pH7.2～7.6, and in the impouring sterile test tube, 121 ℃, 15-20 minutes autoclavings are preserved subsequent use in the rearmounted 4 ℃ of refrigerators of taking-up; Solution example is done 2 times of dilutions, totally 8 dilution factors with culture fluid 1:10 dilution beginning during experiment.
3. positive control drug: ribavirin (RBV) Jiangxi Huiren Pharmaceutical Co., Ltd produces.
4
.Method of testing: 1. with people embryo epithelial cell (2～4) * 10
50.1ml be inoculated into 96 hole micro plastics culture plates, 37 ℃ of every hole 100 μ l, 5%CO
2Cultivated 1～2 day, and grew into cell monolayer.Cell growth medium is MEM 100ml, contains new life or hyclone 10%, 3% glutamine 1%, penicillin and each 100U/ml of streptomycin, NaHCO3 5%; When cell grows up to monolayer, abandon growth-promoting media, need before the virus inoculation to wash cell two times with the PBS or the Hanks liquid of preparatory temperature.
2. control is done, and adds 100 μ l, 10～100TCID
50The viral suspension infection cell, 37 ℃ of absorption 1～2h abandon viral liquid, add again contain the variable concentrations testing compound keep liquid 100 μ l, each concentration 2～3 hole, 37 ℃ of 5%CO
2Incubation continues to cultivate.If normal cell contrast, drug toxicity contrast, virus control, ribavirin (RBV) positive control and viral TCID
50Titration.
3. under inverted microscope, check every day and write down cytopathy (<25% is a plus sige, 25
~50% is two plus siges, 50
~75% is three plus siges, 75
~100% is four plus siges), (do not add testing compound) up to the virus control hole and occur 3
~Be the experiment terminal point during cytopathy of 4 plus siges.Write down each porocyte lesion degree, calculate every group of average cell lesion degree, compare with the virus control group, calculating inhibition 50% cytopathic compound concentration with Reed and Muench method is half-inhibition concentration (IC
50).
4. press the toxicity of criterion calculation medicine pair cell 3. simultaneously, calculating generation 50% cytopathic compound concentration with Reed and Muench method is half toxic concentration (TD
50).
5. TD
50/ IC
50Be selection index (SI).
5. experimental result
Test Example 2: the laboratory observation of the external resisiting influenza virus first of Chinese medicine composition type
Test philosophy: with MDCK (MDCK) is virus host, and working sample suppresses influenza virus A type and causes the mdck cell lesion degree.
Test material and method:
1. Strain :/243/72 (H3N2) prevented in influenza virus A type A/ Guangdong.
2. sample treatment: get that thick paste that embodiment 2,4,6,8,10 makes is dissolved in water and to process the solution bottling of 1000mg/ml respectively subsequent use; 3000rpm gets supernatant after centrifugal 20 minutes, and the sodium citrate with 50% is transferred pH7.2～7.6, and in the impouring sterile test tube, 121 ℃, 15-20 minutes autoclavings are preserved subsequent use in the rearmounted 4 ℃ of refrigerators of taking-up; Solution example is done 2 times of dilutions, totally 8 dilution factors with culture fluid 1:10 dilution beginning during experiment.
3. positive control drug: oseltamivir phosphate capsule.
4. method of testing: mdck cell kind 96 well culture plates; Difference influenza virus infection first type A/ anti-/ 243/72 (H3N2) (infective dose is 100 TCID50) in Guangdong adsorbed 2 hours after 24 hours, abandoned viral liquid; Add sample by above dilution factor; Establish cell control well and virus control hole simultaneously, 24 h observation cytopathy degree (CPE) are with the medium effective concentration (IC of Reed-Muench method difference calculation sample
50), and calculate medicament selection index (SI).
5. experimental result
Test Example 3: the clinical observation of traditional Chinese medicine composition for treating rhinovirus upper respiratory tract infection
1.1 data and method
1.1.1 clinical data
This group case is the patient of the rhinovirus upper respiratory tract infection that in December, 2009 to 2012 makes a definite diagnosis year March; 1 ~ 69 years old age; The patient who meets following Chinese and western medicine diagnostic criteria, 150 routine patients are divided into treatment group (Chinese medicine composition) 75 examples at random, matched group (ribavirin) 75 examples.Treatment is organized 75 examples and is assigned randomly to each 15 example of 2,4,6,8,10 groups of embodiment examples (being called for short treatment group A, B, C, D, E); Matched group 75 examples are divided into five groups of (being called for short control group A, B, C, D, E) each 15 examples at random, two groups of not statistically significants on sex, age, the course of disease and the state of an illness distribute (P>0.05).
1.1.2 diagnostic criteria
1.1.2.1 Western medicine diagnose standard
(1) clinical symptoms: sure rhinovirus infection medical history is arranged, Acute onset, the course of disease≤2 day; With symptoms such as cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynxs;
(2) health check-up: pharyngeal congestion, antiadoncus, two pulmonary respiration sounds are coarse slightly or not coarse;
(3) Serological testing: it is positive to adopt the RT-PCR method to detect rhinovirus, the conventional leukocyte of peripheral blood calculate and classification all between normal range or numeration of leukocyte low;
(4) X line chest film inspection is normal basically.
1.1.2.2 tcm diagnosis standard:
Be principal character with symptoms such as cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynxs clinically, reddish tongue, tongue be BOHUANG, rolling pulse slightly.
1.2 Therapeutic Method
The treatment group gives Chinese medicinal composition granules, and is oral, and every day twice, each consumption is equivalent to each raw medicinal herbs 10g (Folium Perillae 15 grams); Matched group is with ribavirin effervescent granule 150mg/ time, and is every day 3 times, oral.The child is cut down according to the circumstance.Be 5 days the course of treatment.
1.3 criterion of therapeutical effect
Criterion of therapeutical effect:
Recovery from illness: treat clinical symptoms signs such as cough in five days, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx and disappear;
Produce effects: treat clinical symptoms signs such as cough in five days, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx and alleviate more than 2/3;
Effectively: treat clinical symptoms signs such as cough in five days, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx and alleviate 2/3～1/3;
Invalid: treating in five days conscious or other symptoms does not all have obvious improvement or increases the weight of.
1.4 result
Chinese medicine composition (treatment group A) the treatment rhinovirus upper respiratory tract infection of utilization embodiment of the present invention example 2; The result shows: compare clinical symptoms such as two groups of patient's total effective rates and medication front and back cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx and improve situation, treatment group A clinical improvements total effective rate 73.11%; Control group A clinical improvements total effective rate 34.66%, treatment group A and control group A comparing difference have statistical significance (P＜0.05).In clinical treatment observation, do not find toxic and side effects.The clinical effectiveness prompting: embodiment of the present invention example 2 traditional Chinese medicine composition for treating rhinovirus upper respiratory tract infection satisfactory effects all are superior to the ribavirin group in Chinese drug-treated group aspect relieve clinical symptoms time and total effective rate and the cure rate.
Chinese medicine composition (treatment group B) the treatment rhinovirus upper respiratory tract infection of utilization embodiment of the present invention example 4; The result shows: compare clinical symptoms such as two groups of patient's total effective rates and medication front and back cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx and improve situation, treatment group B clinical improvements total effective rate 75.23%; Matched group B clinical improvements total effective rate 32.95%; Treatment group B and matched group B comparing difference have statistical significance (P＜0.05).In clinical treatment observation, do not find toxic and side effects.The clinical effectiveness prompting: embodiment of the present invention example 4 traditional Chinese medicine composition for treating rhinovirus upper respiratory tract infection satisfactory effects all are superior to the ribavirin group in Chinese drug-treated group aspect relieve clinical symptoms time and total effective rate and the cure rate.
Chinese medicine composition (treatment group C) the treatment rhinovirus upper respiratory tract infection of utilization embodiment of the present invention example 6; The result shows: compare two groups of patient's total effective rates and medication front and back cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx clinical symptoms improvement situation, treatment group C clinical improvements total effective rate 83.52%; Matched group C clinical improvements total effective rate 39.15%; Treatment group C and matched group C comparing difference have statistical significance (P＜0.05).In clinical treatment observation, do not find toxic and side effects.The clinical effectiveness prompting: embodiment of the present invention example 6 traditional Chinese medicine composition for treating rhinovirus upper respiratory tract infection satisfactory effects all are superior to the ribavirin group in Chinese drug-treated group aspect relieve clinical symptoms time and total effective rate and the cure rate.
Chinese medicine composition (treatment group D) the treatment rhinovirus upper respiratory tract infection of utilization embodiment of the present invention example 8; The result shows: compare clinical symptoms such as two groups of patient's total effective rates and medication front and back cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx and improve situation, treatment group D clinical improvements total effective rate 90.57%; Matched group D clinical improvements total effective rate 46.55%; Treatment group D and matched group D comparing difference have statistical significance (P＜0.05).In clinical treatment observation, do not find toxic and side effects.The clinical effectiveness prompting: embodiment of the present invention example 8 traditional Chinese medicine composition for treating rhinovirus upper respiratory tract infection satisfactory effects all are superior to the ribavirin group in Chinese drug-treated group aspect relieve clinical symptoms time and total effective rate and the cure rate.
Chinese medicine composition (treatment group E) the treatment rhinovirus upper respiratory tract infection of utilization embodiment of the present invention example 10; The result shows: compare clinical symptoms such as two groups of patient's total effective rates and medication front and back cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx and improve situation, treatment group E clinical improvements total effective rate 88.77%; Matched group E clinical improvements total effective rate 46.96%; Treatment group E and matched group E comparing difference have statistical significance (P＜0.05).In clinical treatment observation, do not find toxic and side effects.The clinical effectiveness prompting: embodiment of the present invention example 10 traditional Chinese medicine composition for treating rhinovirus upper respiratory tract infection satisfactory effects all are superior to the ribavirin group in Chinese drug-treated group aspect relieve clinical symptoms time and total effective rate and the cure rate.
Test Example 4: the clinical observation of traditional Chinese medicine composition for treating influenza A virus upper respiratory tract infection
1.1 data and method
1.1.1 clinical data
This group case is the patient of the influenza A virus upper respiratory tract infection that in December, 2009 to 2012 makes a definite diagnosis year March; 1 ~ 70 years old age; The patient who meets following Chinese and western medicine diagnostic criteria, 150 routine patients are divided into treatment group (Chinese medicine composition) 75 examples at random, matched group (ribavirin) 75 examples.Treatment is organized 75 examples and is assigned randomly to each 15 example of 2,4,6,8,10 groups of embodiment examples (being called for short treatment group A, B, C, D, E); Matched group 75 examples are divided into five groups of (being called for short control group A, B, C, D, E) each 15 examples at random, two groups of not statistically significants on sex, age, the course of disease and the state of an illness distribute (P>0.05).
1.1.2 diagnostic criteria
1.1.2.1 Western medicine diagnose standard
(1) clinical symptoms: have sure influenza virus A type to infect medical history, Acute onset, the course of disease≤2 day; With symptoms such as cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx pain, systemic pain, hoarseness;
(2) health check-up: pharyngeal congestion, antiadoncus, two pulmonary respiration sounds are coarse slightly or not coarse;
(3) Serological testing: it is positive to adopt the RT-PCR method to detect influenza virus A type, the conventional leukocyte of peripheral blood calculate and classification all between normal range or numeration of leukocyte low;
(4) X line chest film inspection is normal basically.
1.1.2.2 tcm diagnosis standard:
Be principal character with symptoms such as cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx pain, systemic pain, hoarseness clinically, reddish tongue, yellow and thin fur, floating and rapid pulse.
1.2 Therapeutic Method
The treatment group gives Chinese medicinal composition granules, and is oral, and every day twice, each consumption is equivalent to each raw medicinal herbs 10g (Folium Perillae 15 grams); Matched group is with ribavirin effervescent granule 150mg/ time, and is every day 3 times, oral.The child is cut down according to the circumstance.Be 5 days the course of treatment.
1.3 criterion of therapeutical effect
Criterion of therapeutical effect:
Recovery from illness: treat clinical symptoms signs such as cough in five days, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx pain, systemic pain, hoarseness and disappear;
Produce effects: treat clinical symptoms signs such as cough in five days, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx pain, systemic pain, hoarseness and alleviate more than 2/3;
Effectively: treat clinical symptoms signs such as cough in five days, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx pain, systemic pain, hoarseness and alleviate 2/3～1/3;
Invalid: treating in five days conscious or other symptoms does not all have obvious improvement or increases the weight of.
1.4 result
Chinese medicine composition (treatment group A) the treatment influenza virus upper respiratory tract infection of utilization embodiment of the present invention example 2; The result shows: compare clinical symptoms such as two groups of patient's total effective rates and medication front and back cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx pain, systemic pain, hoarseness and improve situation, treatment group A clinical improvements total effective rate 74.23%; Control group A clinical improvements total effective rate 33.09%; Treatment group A and control group A comparing difference have statistical significance (P＜0.05).In clinical treatment observation, do not find toxic and side effects.The clinical effectiveness prompting: embodiment of the present invention 2 traditional Chinese medicine composition for treating influenza virus upper respiratory tract infection satisfactory effects all are superior to the ribavirin group in Chinese drug-treated group aspect relieve clinical symptoms time and total effective rate and the cure rate.
Chinese medicine composition (treatment group B) the treatment influenza virus upper respiratory tract infection of utilization embodiment of the present invention example 4; The result shows: compare clinical symptoms such as two groups of patient's total effective rates and medication front and back cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx pain, systemic pain, hoarseness and improve situation, treatment group B clinical improvements total effective rate 76.19%; Matched group B clinical improvements total effective rate 35.22%; Treatment group B and matched group B comparing difference have statistical significance (P＜0.05).In clinical treatment observation, do not find toxic and side effects.The clinical effectiveness prompting: embodiment of the present invention example 4 traditional Chinese medicine composition for treating influenza virus upper respiratory tract infection satisfactory effects all are superior to the ribavirin group in Chinese drug-treated group aspect relieve clinical symptoms time and total effective rate and the cure rate.
Chinese medicine composition (treatment group C) the treatment influenza virus upper respiratory tract infection of utilization embodiment of the present invention example 6; The result shows: compare clinical symptoms such as two groups of patient's total effective rates and medication front and back cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx pain, systemic pain, hoarseness and improve situation, treatment group C clinical improvements total effective rate 82.12%; Matched group C clinical improvements total effective rate 40.09%; Treatment group C and matched group C comparing difference have statistical significance (P＜0.05).In clinical treatment observation, do not find toxic and side effects.The clinical effectiveness prompting: embodiment of the present invention example 6 drug compositions treatment influenza virus upper respiratory tract infection satisfactory effect all is superior to the ribavirin group in Chinese drug-treated group aspect relieve clinical symptoms time and total effective rate and the cure rate.
Chinese medicine composition (treatment group D) the treatment influenza virus upper respiratory tract infection of utilization embodiment of the present invention example 8; The result shows: compare clinical symptoms such as two groups of patient's total effective rates and medication front and back cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx pain, systemic pain, hoarseness and improve situation, treatment group D clinical improvements total effective rate 90.31%; Matched group D clinical improvements total effective rate 46.23%; Treatment group D and matched group D comparing difference have statistical significance (P＜0.05).In clinical treatment observation, do not find toxic and side effects.The clinical effectiveness prompting: embodiment of the present invention example 8 traditional Chinese medicine composition for treating influenza virus upper respiratory tract infection satisfactory effects all are superior to the ribavirin group in Chinese drug-treated group aspect relieve clinical symptoms time and total effective rate and the cure rate.
Chinese medicine composition (treatment group E) the treatment influenza virus upper respiratory tract infection of utilization embodiment of the present invention example 10; The result shows: compare clinical symptoms such as two groups of patient's total effective rates and medication front and back cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx pain, systemic pain, hoarseness and improve situation, treatment group E clinical improvements total effective rate 81.15%; Matched group E clinical improvements total effective rate 42.87%; Treatment group E and matched group E comparing difference have statistical significance (P＜0.05).In clinical treatment observation, do not find toxic and side effects.The clinical effectiveness prompting: embodiment of the present invention example 10 traditional Chinese medicine composition for treating influenza virus upper respiratory tract infection satisfactory effects all are superior to the ribavirin group in Chinese drug-treated group aspect relieve clinical symptoms time and total effective rate and the cure rate.
Above content is to combine concrete preferred implementation to the further explain that the present invention did, and can not assert that practical implementation of the present invention is confined to these explanations.For the those of ordinary skill of technical field under the present invention, under the prerequisite that does not break away from the present invention's design, can also make some simple deduction or replace, all should be regarded as belonging to protection scope of the present invention.
Claims (13)
1. a Chinese medicine composition of treating upper respiratory tract infection is characterized in that: the crude drug that comprises following parts by weight: Folium Perillae 5-25 gram, Radix Platycodonis 5-25 gram, Fructus Arctii 5-25 gram, Rhizoma Cynanchi Stauntonii 5-25 gram, Radix Bupleuri 5-25 gram, Fructus Perillae 5-25 gram, Herba Schizonepetae 5-25 gram, Radix Scutellariae 5-25 gram, Cortex Mori 5-25 gram, Radix Glycyrrhizae 1-15 gram.
2. the Chinese medicine composition of treatment upper respiratory tract infection according to claim 1, wherein the consumption of crude drug can also be: Folium Perillae 5-20 gram, Radix Platycodonis 5-20 gram, Fructus Arctii 5-20 gram, Rhizoma Cynanchi Stauntonii 5-20 gram, Radix Bupleuri 5-20 gram, Fructus Perillae 5-20 gram, Herba Schizonepetae 5-20 gram, Radix Scutellariae 5-20 gram, Cortex Mori 5-20 gram, Radix Glycyrrhizae 3-10 gram.
3. the Chinese medicine composition of treatment upper respiratory tract infection according to claim 2, wherein crude drug also has: Folium Mori 5-20 gram or Radix Asteris 5-20 gram.
4. the Chinese medicine composition of treatment upper respiratory tract infection according to claim 3, wherein crude drug also has: Folium Eriobotryae 5-20 gram or Radix Stemonae 5-20 gram.
5. the Chinese medicine composition of treatment upper respiratory tract infection according to claim 4, wherein crude drug also has: Herba Ephedrae 5-20 gram or Pericarpium Citri Reticulatae 5-20 gram.
6. the Chinese medicine composition of treatment upper respiratory tract infection according to claim 5, wherein crude drug also has: Pumex 5-20 gram or Concretio Silicea Bambusae 5-20 gram.
7. the method for preparing of claim 1 or 2 said Chinese medicine compositions, it comprises the following steps:
8. the method for preparing of the said Chinese medicine composition of claim 3, it comprises the following steps:
9. the method for preparing of the said Chinese medicine composition of claim 4, it comprises the following steps:
gets Folium Perillae, Radix Platycodonis, Fructus Arctii, Rhizoma Cynanchi Stauntonii, Radix Bupleuri, Fructus Perillae, Herba Schizonepetae, Radix Scutellariae, Cortex Mori, Radix Glycyrrhizae, Folium Mori or Radix Asteris, Folium Eriobotryae or Radix Stemonae decocte with water merging filtrate, concentrates, cools off; Adding ethanol makes and contains alcohol amount 20-80% (V/V); Reclaim ethanol; Make supernatant concentration become thick paste, subsequent use;
10. the method for preparing of the said Chinese medicine composition of claim 5, it comprises the following steps:
adds capsule adjuvant commonly used with the thick paste of preparation; Dry, pulverizing incapsulates, and can be prepared into the capsule of treatment upper respiratory tract infection; Or thick paste and granule adjuvant commonly used mixed, granulate, dry be distributed into bag, can be prepared into the granule of treating upper respiratory tract infection; Or thick paste and oral liquid adjuvant commonly used mixed, boiling, thin up leaves standstill, and filters, and mixing is distributed into bottle, can be prepared into the oral liquid of treating upper respiratory tract infection; Or thick paste added sucrose, correctives, antiseptic, and boiling, thin up is to 1000ml; Leave standstill, filter mixing; Packing promptly gets the syrup of treating upper respiratory tract infection, wherein said sucrose weight＞450g; Said correctives is stevioside, saccharin sodium, acesulfame-K, glycyrrhizin, thiacyclohexane sulfamic acid, agedoite, alcohol sugar, radix asparagi sweet extract, Mentholum, various essence and various fruity material; Consumption is 0.1 ~ 10%, and said antiseptic is sorbic acid and k-na salt consumption thereof for＜0.3%, methyl hydroxybenzoate class consumption is＜0.05%, and the packaging material that said packing is used is vial, plastic bottle; Maybe thick paste and the tablet adjuvant commonly used with preparation mix, tabletting, can be prepared into the tablet of treating upper respiratory tract infection.
11. the method for preparing of the said Chinese medicine composition of claim 6, it comprises the following steps:
12. the Chinese medicine composition according to the described treatment upper respiratory tract infection of claim 1～6 is characterized in that: the dosage form of described compositions is: capsule, oral liquid, granule, syrup, tablet, effervescent granule, drop pill, aerosol, spray, gargarisma, collutory; Said tablet is oral cavity disintegration tablet, effervescent tablet.
13. the Chinese medicine composition according to the described treatment upper respiratory tract infection of claim 1～6 is characterized in that: can be used for the upper respiratory tract infection of treating or preventing to be caused clinically by influenza virus, rhinovirus, coronavirus, parainfluenza virus, respiratory syncytial virus, adenovirus etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101579309A CN102641335A (en) | 2012-05-21 | 2012-05-21 | Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101579309A CN102641335A (en) | 2012-05-21 | 2012-05-21 | Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102641335A true CN102641335A (en) | 2012-08-22 |
Family
ID=46654579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101579309A Pending CN102641335A (en) | 2012-05-21 | 2012-05-21 | Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102641335A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103704399A (en) * | 2013-12-07 | 2014-04-09 | 哈尔滨升益生物科技开发有限公司 | Formula of loquat comforting tea for upper respiratory infections, and production method thereof |
| CN103768308A (en) * | 2014-02-25 | 2014-05-07 | 王晖 | Medicament composition for treating upper respiratory infections and preparation method thereof |
| CN105998599A (en) * | 2016-04-29 | 2016-10-12 | 深圳市中医院 | Traditional Chinese medicine composition for treating viral respiratory tract infection and preparation method thereof |
| CN107929503A (en) * | 2017-12-15 | 2018-04-20 | 曲敬来 | A kind of Chinese medicine composition for treating disease of viral infection and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125610A (en) * | 1995-10-27 | 1996-07-03 | 刘启庭 | Bagged instant preparation for cold |
| US6063383A (en) * | 1999-01-28 | 2000-05-16 | Hsu; Wu-Ching | Pharmaceutical suppository composites for fever and influenza and method of producing the composites |
| JP2005255662A (en) * | 2004-05-11 | 2005-09-22 | Kokuhi Tei | Plant component mixture for beverage extraction, mixed liquor of plant component and plant component mixture |
| CN1788782A (en) * | 2004-12-16 | 2006-06-21 | 神奇梵净山铜仁药业有限公司 | Loquat leaf extractum for nourishing lung and relieving cough |
| CN101147788A (en) * | 2007-04-11 | 2008-03-26 | 秦庆吉 | Medicine for treating cold and upper respiratory tract infection and its lung inflammation |
| CN101219193A (en) * | 2008-01-15 | 2008-07-16 | 陆小左 | Medicament for clearing heat, eliminating phlegm and relieving cough |
| CN101468089A (en) * | 2007-12-26 | 2009-07-01 | 天津中新药业集团股份有限公司达仁堂制药厂 | Chinese medicinal composition for diffusing lung, relieving exterior syndrome, suppressing cough and reducing phlegm and preparation method thereof |
| CN101780237A (en) * | 2010-04-20 | 2010-07-21 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating cough and preparation method thereof |
| CN102048973A (en) * | 2010-10-28 | 2011-05-11 | 闫吉强 | Medicament for treating cold |
-
2012
- 2012-05-21 CN CN2012101579309A patent/CN102641335A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125610A (en) * | 1995-10-27 | 1996-07-03 | 刘启庭 | Bagged instant preparation for cold |
| US6063383A (en) * | 1999-01-28 | 2000-05-16 | Hsu; Wu-Ching | Pharmaceutical suppository composites for fever and influenza and method of producing the composites |
| JP2005255662A (en) * | 2004-05-11 | 2005-09-22 | Kokuhi Tei | Plant component mixture for beverage extraction, mixed liquor of plant component and plant component mixture |
| CN1788782A (en) * | 2004-12-16 | 2006-06-21 | 神奇梵净山铜仁药业有限公司 | Loquat leaf extractum for nourishing lung and relieving cough |
| CN101147788A (en) * | 2007-04-11 | 2008-03-26 | 秦庆吉 | Medicine for treating cold and upper respiratory tract infection and its lung inflammation |
| CN101468089A (en) * | 2007-12-26 | 2009-07-01 | 天津中新药业集团股份有限公司达仁堂制药厂 | Chinese medicinal composition for diffusing lung, relieving exterior syndrome, suppressing cough and reducing phlegm and preparation method thereof |
| CN101219193A (en) * | 2008-01-15 | 2008-07-16 | 陆小左 | Medicament for clearing heat, eliminating phlegm and relieving cough |
| CN101780237A (en) * | 2010-04-20 | 2010-07-21 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating cough and preparation method thereof |
| CN102048973A (en) * | 2010-10-28 | 2011-05-11 | 闫吉强 | Medicament for treating cold |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103704399A (en) * | 2013-12-07 | 2014-04-09 | 哈尔滨升益生物科技开发有限公司 | Formula of loquat comforting tea for upper respiratory infections, and production method thereof |
| CN103768308A (en) * | 2014-02-25 | 2014-05-07 | 王晖 | Medicament composition for treating upper respiratory infections and preparation method thereof |
| CN103768308B (en) * | 2014-02-25 | 2016-05-04 | 王晖 | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof |
| CN105998599A (en) * | 2016-04-29 | 2016-10-12 | 深圳市中医院 | Traditional Chinese medicine composition for treating viral respiratory tract infection and preparation method thereof |
| CN107929503A (en) * | 2017-12-15 | 2018-04-20 | 曲敬来 | A kind of Chinese medicine composition for treating disease of viral infection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102641356B (en) | Traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and preparation method thereof | |
| CN106138360A (en) | A kind of Chinese medicine composition and preparation method thereof, application | |
| CN102657804B (en) | Traditional Chinese medical composition for treatment of viral influenza and preparation method thereof | |
| CN105998599A (en) | Traditional Chinese medicine composition for treating viral respiratory tract infection and preparation method thereof | |
| CN102319367A (en) | Medicine used for treating chronic pharyngolaryngitis and vocal cord diseases | |
| CN102641335A (en) | Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof | |
| CN101023996B (en) | Chinese medicine for treating exogenous epidemic disease and anemopyretic cold | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| WO2014190555A1 (en) | Traditional chinese medicine composition for resisting influenza a virus infection and relieving cough, and preparation method therefor | |
| CN103705890A (en) | Pharmaceutical composition with function of removing heat from lung to relieve cough | |
| CN110193061A (en) | A kind of preparation and application of the Chinese herbal granules treating or preventing influenza virus of children infection | |
| WO2011143844A1 (en) | Traditional chinese medicine composition for treating infection of influenza a virus subtype and preparation method thereof | |
| CN102188574B (en) | One treats bronchitic Chinese medicine composition of influenza A virus and preparation method thereof | |
| CN102552807A (en) | Chinese medicine for curing air temperature type flue and preparation method and application thereof | |
| CN102552789B (en) | Chinese medicine for treating damp-warm flu and preparation method and application thereof | |
| CN105106601A (en) | Medicinal preparation for treating acute nasopharyngitis | |
| CN105327182A (en) | Medicine for treating child pertussis and preparation method thereof | |
| CN104721624A (en) | Internal medicament for treating adenovirus pneumonia and preparation method of internal medicament | |
| CN104173830A (en) | Medicament for reconciling interior syndromes and relieving exterior syndromes for high fever of cold in winter and preparation method thereof | |
| CN106421314A (en) | Traditional Chinese medicinal composition for treating viral respiratory infection and preparation method of traditional Chinese medicinal composition | |
| CN115300544B (en) | Traditional Chinese medicine composition and patch for dispelling wind, relieving exterior syndrome, detumescence and inducing resuscitation and preparation method thereof | |
| CN108815329A (en) | A kind of Chinese medicine composition and preparation method thereof for treating flu | |
| CN102670959B (en) | Anti-influenza Chinese herba preparation and preparation method thereof | |
| CN102058792A (en) | Traditional Chinese medicine preparation for treatment of cold and cough | |
| CN105796966A (en) | Traditional Chinese medicine composition for preventing and treating chronic fatigue syndromes and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120822 |